Lupin launches Nystatin and Triamcinolone Acetonide in the US market

The company has launched the product after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a regulatory filing.

Mumbai: Through a recent press release the drug maker Lupin said it has launched skin-treatment cream Nystatin and Triamcinolone Acetonide in the US market.

The company has launched the product after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a regulatory filing.

Nystatin is an antifungal medicine that fights infections caused by fungus. Triamcinolone is a steroid. It reduces the actions of chemicals in the body that cause inflammation.

Nystatin and triamcinolone topical (for the skin) is a combination medicine used to treat skin infections caused by fungus or yeast.

Lupin's product is the generic equivalent of Taro Pharmaceuticals' Nystatin and Triamcinolone Acetonide Cream indicated for the treatment of cutaneous candidiasis.

Cutaneous candidiasis and other forms of candidosis are infections caused by the yeast Candida albicans or other Candida species. Yeasts are unicellular fungi that typically reproduce by budding, a process that entails a progeny pinching off of the mother cell.

As per IQVIA MAT September 2018 data, the cream had annual sales of USD 54.3 million in the US.